ObjectiveTo investigate the effects of raltitrexed, and raltitrexed combined with oxaliplatin or irinotecan on transaminase in patients with advanced colorectal cancer.
MethodsForty-eight patients with advanced colorectal cancer were divided into group A(13 case) group B(23 cases) and group C(12 cases) according to the chemotherapy regimen.The A group, B group and C group were treated with raltitrexed monotherapy, chemotherapy of raltitrexed combined with oxaliplatin and raltitrexed combined with irinotecan, respectively.The effects of three regimens on the levels of AST and ALT in patients with advanced colorectal cancer were analyzed.
ResultsAfter three groups were treated with three or more cycles of chemotherapy, the proportions of AST in normal range in group A, B and C were 53.85%, 86.96% and 83.33%, respectively, the proportions of ALT in normal range in group A, B and C were 92.31%, 91.30% and 100%, respectively, and the differences of the AST and ALT grading among three groups were not statistically significant(P>0.05).The differences of the ALT in patients with liver metastasis among three groups were not statistically significant(P>0.05), and the level of AST in group C were higher than that in group A and group B(P < 0.01 and P < 0.05).The levels of AST and ALT in patients without liver metastasis of group B and group C were lower than those of group A(P < 0.05 to P < 0.01).The differences of the ALT and AST in patients with different primary lesions among three groups were not statistically significant(P>0.05).
ConclusionsThe raltitrexed-based second-line treatment can be used as an effective palliative treatment in patients with advanced colorectal cancer, which is worthy of further promotion.
DownLoad: